Profile of lenvatinib in the treatment of hepatocellular carcinoma: design, development, potential place in therapy and network meta-analysis of hepatitis B and hepatitis C in all Phase III trials

Purpose: Sorafenib is the only approved drug in first-line treatment for hepatocellular carcinoma. Recently, the Phase III REFLECT trial proved lenvatinib not inferior to sorafenib, potentially establishing a new standard of care in this setting. The study showed that both have similar overall survi...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Onco Targets Ther
Main Authors: Casadei Gardini, Andrea, Puzzoni, Marco, Montagnani, Francesco, Marisi, Giorgia, Tamburini, Emiliano, Cucchetti, Alessandro, Solaini, Leonardo, Foschi, Francesco Giuseppe, Conti, Fabio, Ercolani, Giorgio, Cascinu, Stefano, Scartozzi, Mario
Formato: Artigo
Idioma:Inglês
Publicado em: Dove 2019
Assuntos:
Original Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6499482/
https://ncbi.nlm.nih.gov/pubmed/31118665
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S192572
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados